Cargando…

STE029逆转肺腺癌EGFR-TKI耐药及其机制研究

BACKGROUND AND OBJECTIVE: Acquired and primary resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is still the bottleneck of clinical treatment of advanced non-small cell lung cancer (NSCLC). STE029 is a novel anticancer drug which consists of 3-hydroxy-3-methylgluta...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720680/
https://www.ncbi.nlm.nih.gov/pubmed/36419390
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.46